

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* <u>Curet Myriam</u> _____ (Last) (First) (Middle) 1020 KIFER ROAD _____ (Street) SUNNYVALE CA 94086 _____ (City) (State) (Zip)			2. Issuer Name and Ticker or Trading Symbol <u>INTUITIVE SURGICAL INC [ ISRG ]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>EVP &amp; Chief Medical Officer</u>		
			3. Date of Earliest Transaction (Month/Day/Year) 11/12/2024					
			4. If Amendment, Date of Original Filed (Month/Day/Year)			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	11/12/2024		M <sup>(1)</sup>		2,257	A	\$177.9867	2,555	D	
Common Stock	11/12/2024		S <sup>(1)</sup>		2,257	D	\$535.9569 <sup>(2)</sup>	298	D	
Common Stock	11/12/2024		M <sup>(1)</sup>		5,000	A	\$182.8333	5,298	D	
Common Stock	11/12/2024		S <sup>(1)</sup>		5,000	D	\$535.9569 <sup>(2)</sup>	298	D	
Common Stock	11/12/2024		M <sup>(1)</sup>		2,199	A	\$229.39	2,497	D	
Common Stock	11/12/2024		S <sup>(1)</sup>		2,199	D	\$535.9569 <sup>(2)</sup>	298	D	
Common Stock	11/12/2024		M <sup>(1)</sup>		4,010	A	\$208.9	4,308	D	
Common Stock	11/12/2024		S <sup>(1)</sup>		4,010	D	\$535.9569 <sup>(2)</sup>	298	D	

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Non-Qualified Stock Option (right to buy)	\$177.9867	11/12/2024		M <sup>(1)</sup>			2,257	(3)	02/28/2030	Common Stock	2,257	\$0.0	0	D	
Non-Qualified Stock Option (right to buy)	\$182.8333	11/12/2024		M <sup>(1)</sup>			5,000	(3)	02/15/2029	Common Stock	5,000	\$0.0	0	D	
Non-Qualified Stock Option (right to buy)	\$208.9	11/12/2024		M <sup>(1)</sup>			4,010	(4)	08/28/2029	Common Stock	4,010	\$0.0	2,005	D	
Non-Qualified Stock Option (right to buy)	\$229.39	11/12/2024		M <sup>(1)</sup>			2,199	(5)	02/27/2030	Common Stock	2,199	\$0.0	2,829	D	

Explanation of Responses:

1. The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on August 13, 2025.
2. The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from \$533.10 to \$538.66 as follows: 4,510 shares sold at \$533.10 to \$534.07; 907 shares sold at \$534.11 to \$534.68; 200 shares sold at \$535.34 to \$536.28; 4,400 shares sold at \$536.46 to \$537.36; 3,437 shares sold at \$537.49 to \$538.36; and 12 shares sold at \$538.66. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
3. Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. The option vests 1/8th six months after the date of grant and 1/48th monthly thereafter.
4. Non-statutory stock option granted pursuant to the 2010 Incentive Award Plan. Option shall vest 7/48 one month after the date of grant and 1/48 each month thereafter.
5. 12.5% of the shares subject to the option vest on the six-month anniversary measured from February 10, 2023, and 1/48th of the total number of shares vest in forty-two (42) successive and equal monthly installments thereafter, subject to Reporting Person's continuous service to the Issuer through each such vesting date.

By: Donna Spinola For: Curet, Myriam      11/13/2024

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

POWER OF ATTORNEY

Know all by these present that the undersigned hereby authorizes Donna Spinola, Stephanie Lim-Ignacio, Thanh Nhan Phan, and Cory Balliet of Intuitive Surgical, Inc. (the "Company") and Mark Roeder and John Williams of Latham & Watkins LLP, and each of them individually, to (i) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer or director of the Company, Forms 3, 4, and 5, and Notices of Proposed Sale of Securities Pursuant to Rule 144 ("Form 144"), in accordance with the requirements of Rule 144 under the Securities Act of 1933, as amended (the "Securities Act"), and other forms as may be required, and any amendments thereto, and cause such forms to be filed with the U.S. Securities and Exchange Commission (the "SEC") pursuant to Section 16(a) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Rule 144 under the Securities Act, relating to the undersigned's ownership of and transactions in securities of the Company and (ii) execute for and on behalf of the undersigned in the undersigned's name, and submit to the SEC, a Form ID, including amendments thereto, and any other documents necessary or appropriate to obtain and/or regenerate codes and passwords enabling the undersigned to make electronic filings with the SEC of reports required by Section 16(a) of the Exchange Act, Rule 144 of the Securities Act or any rule or regulation of the SEC. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorneys-in-fact, or such attorneys-in-fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act or Rule 144 under the Securities Act.

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 and Form 144 with respect to the undersigned's holdings of, and transactions in, securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this day of July 25, 2024.

/s/ Myriam Curet  
MYRIAM CURET